Ubs Asset Management Americas Inc Protagonist Therapeutics, Inc Transaction History
Ubs Asset Management Americas Inc
- $277 Billion
- Q1 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 335,318 shares of PTGX stock, worth $11.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
335,318
Previous 289,079
16.0%
Holding current value
$11.6 Million
Previous $6.63 Million
46.35%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PTGX
# of Institutions
187Shares Held
59.5MCall Options Held
35.7KPut Options Held
72.3K-
Farallon Capital Management LLC San Francisco, CA5.74MShares$199 Million0.77% of portfolio
-
Black Rock Inc. New York, NY5.57MShares$193 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.32MShares$184 Million2.47% of portfolio
-
Bvf Inc San Francisco, CA3.76MShares$130 Million3.25% of portfolio
-
State Street Corp Boston, MA3.27MShares$113 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.7B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...